Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Mallinckrodt
US Army
Covington
Dow
Cerilliant
Deloitte
Daiichi Sankyo

Generated: July 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022224

« Back to Dashboard

NDA 022224 describes TRILIPIX, which is a drug marketed by Abbvie and is included in one NDA. It is available from four suppliers. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the TRILIPIX profile page.

The generic ingredient in TRILIPIX is choline fenofibrate. There are one hundred and two drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.
Summary for 022224
Tradename:TRILIPIX
Applicant:Abbvie
Ingredient:choline fenofibrate
Patents:1
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 022224
Generic Entry Date for 022224*:
Constraining patent/regulatory exclusivity:
Dosage::
CAPSULE, DELAYED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022224
Suppliers and Packaging for NDA: 022224
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224 NDA AbbVie Inc. 0074-3161 N 0074-3161-90
TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224 NDA AbbVie Inc. 0074-3162 N 0074-3162-90

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrengthEQ 45MG FENOFIBRIC ACID
Approval Date:Dec 15, 2008TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jan 7, 2025Product Flag?Substance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrengthEQ 135MG FENOFIBRIC ACID
Approval Date:Dec 15, 2008TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jan 7, 2025Product Flag?Substance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Merck
Medtronic
Fuji
US Department of Justice
Teva
Federal Trade Commission
QuintilesIMS
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.